caa a22 4500 445311703 CHVBK 20180317142632.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s11095-011-0392-y doi (NATIONALLICENCE)springer-10.1007/s11095-011-0392-y Controlled Delivery Systems: From Pharmaceuticals to Cells and Genes [Elektronische Daten] [Elizabeth Balmayor, Helena Azevedo, Rui Reis] ABSTRACT: During the last few decades, a fair amount of scientific investigation has focused on developing novel and efficient drug delivery systems. According to different clinical needs, specific biopharmaceutical carriers have been proposed. Micro- and nanoparticulated systems, membranes and films, gels and even microelectronic chips have been successfully applied in order to deliver biopharmaceuticals via different anatomical routes. The ultimate goal is to deliver the potential drugs to target tissues, where regeneration or therapies (chemotherapy, antibiotics, and analgesics) are needed. Thereby, the bioactive molecule should be protected against environmental degradation. Delivery should be achieved in a dose- and time-correct manner. Drug delivery systems (DDS) have been conceived to provide improvements in drug administration such as ability to enhance the stability, absorption and therapeutic concentration of the molecules in combination with a long-term and controlled release of the drug. Moreover, the adverse effects related with some drugs can be reduced, and patient compliance could be improved. Recent advances in biotechnology, pharmaceutical sciences, molecular biology, polymer chemistry and nanotechnology are now opening up exciting possibilities in the field of DDS. However, it is also recognized that there are several key obstacles to overcome in bringing such approaches into routine clinical use. This review describes the present state-of-the-art DDS, with examples of current clinical applications, and the promises and challenges for the future in this innovative field. Springer Science+Business Media, LLC, 2011 cell encapsulation nationallicence DDS routes of administration nationallicence gene therapy nationallicence growth factors nationallicence nanotechnology nationallicence regenerative medicine nationallicence BMP-2 : bone morphogenetic protein 2 nationallicence BSA : bovine serum albumin nationallicence cDNA : complementary DNA nationallicence DDS : drug delivery systems nationallicence ECM : extracellular matrix nationallicence HEMA-MMA : Hydroxyethylmethacrylate- Methyl methacrylate nationallicence IGF-I : insulin-like growth factor 1 nationallicence PC12 : cell line derived from a pheochromocytoma of the rat adrenal medulla nationallicence PDGF : platelet-derived growth factor nationallicence PLA-PEG : Polylactic acid-polyethylene glycol nationallicence PLGA-m-PEG : Poly(lactic-co-glycolic acid)-methoxy-polyethylene glycol nationallicence VEGF : vascular endothelial growth factor nationallicence Balmayor Elizabeth 3B's Research Group—Biomaterials, Biodegradables and Biomimetics Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, University of Minho, AvePark,, 4806-909, Guimarães, Taipas, Portugal aut Azevedo Helena 3B's Research Group—Biomaterials, Biodegradables and Biomimetics Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, University of Minho, AvePark,, 4806-909, Guimarães, Taipas, Portugal aut Reis Rui Institute for Biotechnology and Bioengineering, PT Government Associated Laboratory, Guimarães, Portugal aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/6(2011-06-01), 1241-1258 0724-8741 28:6<1241 2011 28 11095 https://doi.org/10.1007/s11095-011-0392-y text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-011-0392-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Balmayor Elizabeth 3B's Research Group—Biomaterials, Biodegradables and Biomimetics Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, University of Minho, AvePark,, 4806-909, Guimarães, Taipas, Portugal aut NATIONALLICENCE 700 1- Azevedo Helena 3B's Research Group—Biomaterials, Biodegradables and Biomimetics Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, University of Minho, AvePark,, 4806-909, Guimarães, Taipas, Portugal aut NATIONALLICENCE 700 1- Reis Rui Institute for Biotechnology and Bioengineering, PT Government Associated Laboratory, Guimarães, Portugal aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/6(2011-06-01), 1241-1258 0724-8741 28:6<1241 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer